September 27, 2016 / 12:17 PM / a year ago

BRIEF-Coherus Biosciences regains development and commercial rights to CHS-0214 from Shire

Sept 27 (Reuters) - Coherus Biosciences Inc. :

* Says has regained from shire plc all development and commercial rights previously licensed for chs-0214 etanercept

* Coherus Biosciences regains development and commercial rights to CHS 0214 from Shire

* As result of termination agreement with Shire, co expects to recognize $162.6 million as collaboration and license revenues in 2016

* CHS-0214 etanercept is a biosimilar candidate to enbrel for Europe, Canada, Brazil, Middle East and other territories

* Remain on track for submission of a CHS-0214 marketing authorization application to european medicines agency in Q4 of 2016 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below